17 terminated. 17 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Terminated 17 |
| Phase 2 | 5 | Terminated 5 |
Follow B-cell Chronic Lymphocytic Leukemia: new trials by email Literature Review of B-cell Chronic Lymphocytic Leukemia trials Research Report on B-cell Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies 0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells - B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Medical College of Wisconsin | 4 | 2022-06-30 | 2024-09-19 |
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Lymphoma, Non-hodgkins | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2019-12-20 | 2022-02-15 |
| A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities Chlorambucil, Obinutuzumab, Placebo - B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Hoffmann-La Roche | 38 | 2015-06-26 | 2021-04-08 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide B-CLL Vaccine, Lenalidomide - B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Baylor College of Medicine | 2 | 2013-02-01 | 2016-02-08 |
| Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia alvespimycin hydrochloride, diagnostic laboratory biomarker analysis, pharmacogenomic studies - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2010-05-01 | 2015-11-04 |
| Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia Forodesine - B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Mundipharma Research Limited | 1 | 2008-07-01 | 2010-03-31 |
| Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM Samalizumab - B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 26 | 2008-06-19 | 2019-03-05 |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia obatoclax mesylate, fludarabine phosphate, rituximab - B-cell Chronic Lymphocytic Leukemia, Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 28 | 2008-01-01 | 2013-09-30 |
| Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alvocidib, pharmacological study, laboratory biomarker analysis - B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Small Lymphocytic Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 24 | 2006-09-01 | 2013-07-02 |
| A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) MyVax - B-Cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Genitope Corporation | 86 | 2006-03-01 | 2008-03-18 |
| Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL CNF2024 (BIIB021) - B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Biogen | 15 | 2006-02-01 | 2009-06-05 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia tanespimycin, rituximab - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2005-04-01 | 2013-06-04 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma oxaliplatin, etoposide - Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2004-11-01 | 2014-02-24 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma ipilimumab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2004-06-01 | 2014-05-30 |
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Lymphoma, Large B-Cell, Diffuse (5) · Burkitt Lymphoma (4) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, Non-Hodgkin (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Intraocular Lymphoma (3) · Leukemia (3) · Leukemia, Hairy Cell (3) · Leukemia, Prolymphocytic (3) · Lymphoma, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Waldenstrom Macroglobulinemia (3) · Hodgkin Disease (2)
Chronic Disease (17) · Disease Attributes (17) · Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Leukemia, B-Cell (17) · Leukemia, Lymphoid (17) · Lymphatic Diseases (17) · Lymphoproliferative Disorders (17) · Neoplasms by Histologic Type (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Neoplasms (16) · Leukemia (14)
Rituximab (4) · fludarabine phosphate (2) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine (1) · Automobiles (1) · Bendamustine Hydrochloride (1) · CTLA-4 Antigen (1) · Chlorambucil (1) · Cyclophosphamide (1) · Etoposide (1) · Fenretinide (1) · Ipilimumab (1) · Lenalidomide (1) · Oxaliplatin (1) · Pharmacogenomic Testing (1)
National Cancer Institute (NCI) (8) · Alexion Pharmaceuticals, Inc. (1) · Asana BioSciences (1) · Baylor College of Medicine (1) · Biogen (1) · Genitope Corporation (1) · Hoffmann-La Roche (1) · Medical College of Wisconsin (1) · Mundipharma Research Limited (1) · Wake Forest University Health Sciences (1)
United States (14) · Spain (2) · Argentina (1) · Israel (1) · Italy (1) · Latvia (1) · United Kingdom (1)
Ajay Gopal (1) · Chris Storgard, MD (1) · James N Kochenderfer, M.D. (1) · Jeffrey Jones (1) · Jennifer Brown (1) · Leslie Andritsos (1) · Lisa McGregor (1) · Malcolm Brenner, MB, PhD (1) · Martha Mims, MD (1) · Niranjan Rao, PhD (1) · Nirav Shah, MD (1) · Stephen Ansell (1) · Thomas Kipps, M.D. (1) · Thomas Lin (1)
U01CA076576 (2), 2014 (1), P30CA012197 (1), P30CA015083 (1), P30CA016058 (1), P30CA021765 (1), R21CA115048 (1), R21CA119519 (1), U01CA062490 (1), U01CA069912 (1)